{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:10:51Z","timestamp":1786119051999,"version":"build-2736575974"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1097\/mol.0b013e32831ac56c","type":"journal-article","created":{"date-parts":[[2008,12,23]],"date-time":"2008-12-23T03:20:09Z","timestamp":1230002409000},"page":"10-16","source":"Crossref","is-referenced-by-count":3,"title":["The effect of antidiabetic drugs on genes regulating lipid metabolism"],"prefix":"10.1097","volume":"20","author":[{"given":"Gerald H","family":"Tomkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210205","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"key":"R2-4-20210205","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"R3-4-20210205","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/BF00252657","article-title":"Plasma lipids and lipoproteins in young insulin-dependent diabetic patients: relationship with control","volume":"21","author":"Lopes-Virella","year":"1981","journal-title":"Diabetologia"},{"issue":"Suppl 2","key":"R4-4-20210205","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.2337\/dc08-s260","article-title":"The intestine as a regulator of cholesterol homeostasis in diabetes","volume":"31","author":"Tomkin","year":"2008","journal-title":"Diabetes Care"},{"key":"R6-4-20210205","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.atherosclerosis.2004.12.033","article-title":"Low density lipoprotein nonesterified fatty acids and lipoprotein lipase in diabetes","volume":"181","author":"Phillips","year":"2005","journal-title":"Atherosclerosis"},{"key":"R8-4-20210205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0021-9150(93)90084-8","article-title":"Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient?","volume":"102","author":"Bowie","year":"1993","journal-title":"Atherosclerosis"},{"key":"R9-4-20210205","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2337\/db05-1593","article-title":"Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives","volume":"55","author":"Sapone","year":"2006","journal-title":"Diabetes"},{"key":"R10-4-20210205","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.dld.2003.09.016","article-title":"Ultrastructural mucosal alterations and increased intestinal permeability in nonceliac, type I diabetic patients","volume":"36","author":"Secondulfo","year":"2004","journal-title":"Dig Liver Dis"},{"key":"R11-4-20210205","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/diabetes.53.9.2217","article-title":"Cholesterol metabolism in type 1 diabetes","volume":"53","author":"Gylling","year":"2004","journal-title":"Diabetes"},{"key":"R12-4-20210205","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2337\/diacare.20.1.90","article-title":"Cholesterol absorption, synthesis and LDL metabolism in NIDDM","volume":"20","author":"Gylling","year":"1997","journal-title":"Diabetes Care"},{"key":"R13-4-20210205","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1155\/EDR.2000.203","article-title":"The relationship between cholesterol absorption and intestinal cholesterol synthesis in the diabetic rat model.","volume":"1","author":"Gleeson","year":"2000","journal-title":"Internat J Exp Diab Res"},{"key":"R14-4-20210205","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jacl.2008.01.008","article-title":"The role of Niemann-Pick C1-like 1 (NPC1L1) in intestinal sterol absorption","volume":"2","author":"Turley","year":"2008","journal-title":"J Clin Lipidol"},{"key":"R15-4-20210205","doi-asserted-by":"crossref","first-page":"G839","DOI":"10.1152\/ajpgi.00061.2008","article-title":"Development and physiological regulation of intestinal lipid absorption. III. Intestinal transporters and cholesterol absorption","volume":"294","author":"Hui","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R16-4-20210205","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"R17-4-20210205","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.cmet.2008.04.001","article-title":"The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1","volume":"7","author":"Ge","year":"2008","journal-title":"Cell Metab"},{"key":"R18-4-20210205","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1007\/s00125-006-0177-8","article-title":"Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein","volume":"49","author":"Lally","year":"2006","journal-title":"Diabetologia"},{"key":"R19-4-20210205","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.metabol.2006.10.028","article-title":"Genes that affect cholesterol synthesis, cholesterol absorption, and chylomicron assembly: the relationship between the liver and intestine in control and streptozotosin diabetic rats","volume":"56","author":"Lally","year":"2007","journal-title":"Metabolism"},{"key":"R20-4-20210205","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1126\/science.290.5497.1771","article-title":"Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters","volume":"290","author":"Berge","year":"2000","journal-title":"Science"},{"key":"R21-4-20210205","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1194\/jlr.M500511-JLR200","article-title":"The mechanism of ABCG5\/ABCG8 in biliary cholesterol secretion in mice","volume":"47","author":"Kosters","year":"2006","journal-title":"J Lipid Res"},{"key":"R22-4-20210205","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.atherosclerosis.2006.09.031","article-title":"The different effect of pioglitazone as compared to insulin on expression of hepatic and intestinal genes regulating postprandial lipoproteins in diabetes","volume":"193","author":"Lally","year":"2007","journal-title":"Atherosclerosis"},{"key":"R23-4-20210205","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2005.08.020","article-title":"Intestinal microsomal triglyceride transfer protein in type 2 diabetic and nondiabetic subjects: the relationship to triglyceride-rich postprandial lipoprotein composition","volume":"187","author":"Phillips","year":"2006","journal-title":"Atherosclerosis"},{"key":"R24-4-20210205","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/en.2004-1143","article-title":"Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian Golden hamster","volume":"146","author":"Lewis","year":"2005","journal-title":"Endocrinology"},{"key":"R25-4-20210205","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1161\/CIRCULATIONAHA.107.739888","article-title":"Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans","volume":"117","author":"Duez","year":"2008","journal-title":"Circulation"},{"key":"R26-4-20210205","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/15604280214277","article-title":"Defective chylomicron synthesis as a cause of delayed particle clearance in diabetes?","volume":"3","author":"Phillips","year":"2002","journal-title":"Int J Exp Diabetes Res"},{"key":"R27-4-20210205","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1161\/ATVBAHA.108.169383","article-title":"Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans","volume":"28","author":"Pavlic","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R28-4-20210205","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00125-003-1052-5","article-title":"Diabetes: mellitus or lipidus?","volume":"46","author":"Shafrir","year":"2003","journal-title":"Diabetologia"},{"key":"R29-4-20210205","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00125-006-0271-y","article-title":"Global gene expression analysis in liver of obese diabetic db\/db mice treated with metformin","volume":"49","author":"Heishi","year":"2006","journal-title":"Diabetologia"},{"key":"R30-4-20210205","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2337\/db07-0381","article-title":"Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP","volume":"57","author":"Kim","year":"2008","journal-title":"Diabetes"},{"key":"R31-4-20210205","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J Clin Invest"},{"key":"R32-4-20210205","doi-asserted-by":"crossref","first-page":"47898","DOI":"10.1074\/jbc.M408149200","article-title":"AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells","volume":"279","author":"Zang","year":"2004","journal-title":"J Biol Chem"},{"key":"R33-4-20210205","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.cellbi.2006.11.033","article-title":"Peroxisome proliferator-activated receptor gamma agonists inhibit adipocyte expression of alpha1-acid glycoprotein","volume":"31","author":"Castriota","year":"2007","journal-title":"Cell Biol Int"},{"key":"R34-4-20210205","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.diabres.2008.01.031","article-title":"Effects of sulfonylurea drugs on adiponectin production from 3T3-L1 adipocytes: implication of different mechanism from pioglitazone","volume":"81","author":"Kanda","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"R35-4-20210205","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"R36-4-20210205","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMe078117","article-title":"Rosiglitazone and cardiotoxicity: weighing the evidence","volume":"357","author":"David","year":"2007","journal-title":"N Engl J Med"},{"key":"R37-4-20210205","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMe078099","article-title":"Rosiglitazone and cardiovascular risk","volume":"356","author":"Psaty","year":"2007","journal-title":"N Engl J Med"},{"key":"R38-4-20210205","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.2337\/dc07-0717","article-title":"Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)","volume":"30","author":"Erdmann","year":"2007","journal-title":"Diabetes Care"},{"key":"R39-4-20210205","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ahj.2007.11.029","article-title":"Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)","volume":"155","author":"Wilcox","year":"2008","journal-title":"Am Heart J"},{"key":"R40-4-20210205","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.2337\/dc06-1903","article-title":"Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia","volume":"30","author":"Deeg","year":"2007","journal-title":"Diabetes Care"},{"key":"R42-4-20210205","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1006\/bbrc.2000.3868","article-title":"Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone","volume":"278","author":"Sakamoto","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"R43-4-20210205","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.2337\/diabetes.54.5.1392","article-title":"Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo","volume":"54","author":"Bogacka","year":"2005","journal-title":"Diabetes"},{"key":"R44-4-20210205","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.diabres.2008.02.001","article-title":"Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus","volume":"81","author":"Kim","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"R45-4-20210205","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2337\/diabetes.54.3.603","article-title":"Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes","volume":"54","author":"Petersen","year":"2005","journal-title":"Diabetes"},{"key":"R46-4-20210205","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.2337\/db07-1828","article-title":"Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content","volume":"57","author":"Ravikumar","year":"2008","journal-title":"Diabetes"},{"key":"R47-4-20210205","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/diabetes.52.6.1364","article-title":"Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes","volume":"52","author":"Bajaj","year":"2003","journal-title":"Diabetes"},{"key":"R48-4-20210205","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1210\/jc.2007-2110","article-title":"Dissociation between the insulin-sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production","volume":"93","author":"Duez","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R49-4-20210205","doi-asserted-by":"crossref","first-page":"E1736","DOI":"10.1152\/ajpendo.00122.2007","article-title":"PPARgamma regulates adipose triglyceride lipase in adipocytes in vitro and in vivo","volume":"293","author":"Kershaw","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R50-4-20210205","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.2337\/diabetes.51.10.2944","article-title":"Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes","volume":"51","author":"Kelley","year":"2002","journal-title":"Diabetes"},{"key":"R51-4-20210205","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/sj.ijo.0803567","article-title":"Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta\/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus","volume":"31","author":"Mensink","year":"2007","journal-title":"Int J Obes (Lond)"},{"key":"R52-4-20210205","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.abb.2008.05.015","article-title":"Pioglitazone induces lipid accumulation in the rat heart despite concomitant reduction in plasma free fatty acid availability","volume":"477","author":"Baranowski","year":"2008","journal-title":"Arch Biochem Biophys"},{"key":"R53-4-20210205","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nm1025","article-title":"PPARs and the complex journey to obesity","volume":"10","author":"Evans","year":"2004","journal-title":"Nat Med"},{"key":"R54-4-20210205","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1373\/clinchem.2007.099747","article-title":"Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment","volume":"54","author":"Lambert","year":"2008","journal-title":"Clin Chem"},{"key":"R55-4-20210205","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1194\/jlr.M700345-JLR200","article-title":"Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse","volume":"48","author":"Valasek","year":"2007","journal-title":"J Lipid Res"},{"key":"R56-4-20210205","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"R57-4-20210205","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1172\/JCI25764","article-title":"Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage","volume":"115","author":"Knauf","year":"2005","journal-title":"J Clin Invest"},{"key":"R58-4-20210205","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1210\/en.2008-0180","article-title":"Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance, and reduces energy expenditure","volume":"149","author":"Knauf","year":"2008","journal-title":"Endocrinology"},{"key":"R59-4-20210205","doi-asserted-by":"crossref","first-page":"R2163","DOI":"10.1152\/ajpregu.00911.2006","article-title":"Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system","volume":"293","author":"D'Alessio","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R60-4-20210205","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2337\/db06-0518","article-title":"Tumor necrosis factor-alpha induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein B48-containing lipoproteins","volume":"56","author":"Qin","year":"2007","journal-title":"Diabetes"},{"key":"R61-4-20210205","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0021-9150(01)00721-3","article-title":"Microsomal triglyceride transfer protein: does insulin resistance play a role in the regulation of chylomicron assembly?","volume":"160","author":"Phillips","year":"2002","journal-title":"Atherosclerosis"},{"key":"R62-4-20210205","doi-asserted-by":"crossref","first-page":"G943","DOI":"10.1152\/ajpgi.00303.2004","article-title":"GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats","volume":"288","author":"Qin","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R63-4-20210205","doi-asserted-by":"crossref","first-page":"E846","DOI":"10.1152\/ajpendo.00030.2008","article-title":"Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes","volume":"294","author":"Cervera","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R64-4-20210205","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.clinthera.2008.05.004","article-title":"Effect of exenatide on 24-h blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study","volume":"30","author":"Schwartz","year":"2008","journal-title":"Clin Ther"},{"key":"R65-4-20210205","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-146-7-200704030-00003","article-title":"The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial","volume":"146","author":"Zinman","year":"2007","journal-title":"Ann Intern Med"},{"key":"R66-4-20210205","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079908X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R67-4-20210205","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00125-006-0340-2","article-title":"Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes","volume":"49","author":"Matikainen","year":"2006","journal-title":"Diabetologia"},{"key":"R68-4-20210205","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2337\/dc07-1441","article-title":"The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose","volume":"31","author":"Utzschneider","year":"2008","journal-title":"Diabetes Care"},{"key":"R69-4-20210205","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"R70-4-20210205","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes.","volume":"358","author":"The Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MOL.0b013e32831ac56c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:28:34Z","timestamp":1786037314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00041433-200902000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0b013e32831ac56c","relation":{},"ISSN":["0957-9672"],"issn-type":[{"value":"0957-9672","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}